New hope for Hard-to-Treat lymphoma? drug targets cancer even when marker is low
NCT ID NCT02588651
First seen Nov 21, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study tested a drug called brentuximab vedotin in 23 people with a rare type of T-cell lymphoma that had stopped responding to or returned after prior chemotherapy. The drug is designed to seek out and kill cancer cells that have a specific marker called CD30, even when levels of that marker are very low. The main goal was to see how many patients' tumors shrank or disappeared after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
-
Wayne State University, Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.